Novolin R
Drug
Novo Nordisk Inc
Total Payments
$166,617
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $90,882 | 4 | 0 |
| 2017 | $75,735 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $166,617 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Memory Advancement with Intranasal Insulin in Type 2 Diabetes (MemAid) | Novo Nordisk Inc | $121,176 | 0 |
| Memory Advancement With Intranasal Insulin in Type 2 Diabetes (MemAid) | Novo Nordisk Inc | $45,441 | 0 |
Top Doctors Receiving Payments for Novolin R
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $166,617 | 6 |
Ad
Manufacturing Companies
- Novo Nordisk Inc $166,617
Product Information
- Type Drug
- Total Payments $166,617
- Total Doctors 0
- Transactions 6
About Novolin R
Novolin R is a drug associated with $166,617 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk Inc.
Payment data is available from 2017 to 2019. In 2019, $90,882 was paid across 4 transactions to 0 doctors.
The most common payment nature for Novolin R is "Unspecified" ($166,617, 100.0% of total).
Novolin R is associated with 2 research studies, including "Memory Advancement with Intranasal Insulin in Type 2 Diabetes (MemAid)" ($121,176).